L&C Bio Co. Ltd (290650) - Total Assets
Based on the latest financial reports, L&C Bio Co. Ltd (290650) holds total assets worth ₩497.94 Billion KRW (≈ $337.45 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 290650 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
L&C Bio Co. Ltd - Total Assets Trend (2015–2024)
This chart illustrates how L&C Bio Co. Ltd's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of L&C Bio Co. Ltd to evaluate the quality of earnings relative to operating cash generation.
L&C Bio Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
L&C Bio Co. Ltd's total assets of ₩497.94 Billion consist of 27.4% current assets and 72.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩18.29 Billion | 3.8% |
| Accounts Receivable | ₩21.73 Billion | 4.6% |
| Inventory | ₩46.78 Billion | 9.8% |
| Property, Plant & Equipment | ₩97.02 Billion | 20.4% |
| Intangible Assets | ₩1.93 Billion | 0.4% |
| Goodwill | ₩197.31 Billion | 41.5% |
Asset Composition Trend (2015–2024)
This chart illustrates how L&C Bio Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see L&C Bio Co. Ltd (290650) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: L&C Bio Co. Ltd's current assets represent 27.4% of total assets in 2024, a decrease from 83.5% in 2015.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2024, down from 6.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 41.5% of total assets.
L&C Bio Co. Ltd Competitors by Total Assets
Key competitors of L&C Bio Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
L&C Bio Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.70 | 1.11 | 12.38 |
| Quick Ratio | 0.47 | 0.57 | 10.18 |
| Cash Ratio | 0.00 | 0.23 | 0.00 |
| Working Capital | ₩-62.47 Billion | ₩10.16 Billion | ₩41.83 Billion |
L&C Bio Co. Ltd - Advanced Valuation Insights
This section examines the relationship between L&C Bio Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.10 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 81.4% |
| Total Assets | ₩475.60 Billion |
| Market Capitalization | $1.44 Billion USD |
Valuation Analysis
Below Book Valuation: The market values L&C Bio Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: L&C Bio Co. Ltd's assets grew by 81.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for L&C Bio Co. Ltd (2015–2024)
The table below shows the annual total assets of L&C Bio Co. Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩475.60 Billion ≈ $322.31 Million |
+81.37% |
| 2023-12-31 | ₩262.23 Billion ≈ $177.71 Million |
+31.30% |
| 2022-12-31 | ₩199.73 Billion ≈ $135.35 Million |
+85.96% |
| 2021-12-31 | ₩107.40 Billion ≈ $72.78 Million |
+33.29% |
| 2020-12-31 | ₩80.58 Billion ≈ $54.60 Million |
+21.67% |
| 2019-12-31 | ₩66.23 Billion ≈ $44.88 Million |
+15.42% |
| 2018-12-31 | ₩57.38 Billion ≈ $38.88 Million |
+180.03% |
| 2017-12-31 | ₩20.49 Billion ≈ $13.89 Million |
+30.84% |
| 2016-12-31 | ₩15.66 Billion ≈ $10.61 Million |
+71.88% |
| 2015-12-31 | ₩9.11 Billion ≈ $6.17 Million |
-- |
About L&C Bio Co. Ltd
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.